These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 2491898)
1. Thrombolysis with systemically administered t-PA in a new venous thrombosis model. Hayden RE; McLear PW; Phillips JG; Dawson SM Laryngoscope; 1989 Jan; 99(1):100-4. PubMed ID: 2491898 [TBL] [Abstract][Full Text] [Related]
2. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model. Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892 [TBL] [Abstract][Full Text] [Related]
3. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Collen D; Stassen JM; De Cock F Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288 [TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
5. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo. Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488 [TBL] [Abstract][Full Text] [Related]
6. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987 [TBL] [Abstract][Full Text] [Related]
8. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833 [TBL] [Abstract][Full Text] [Related]
9. Experimental prevention of free flap thrombosis. I: A model of free flap failure. Atchabahian A; Masquelet AC Microsurgery; 1996; 17(12):710-3. PubMed ID: 9588717 [TBL] [Abstract][Full Text] [Related]
10. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Wang YX; da Cunha V; Vincelette J; Zhao L; Nagashima M; Kawai K; Yuan S; Emayan K; Islam I; Hosoya J; Sullivan ME; Dole WP; Morser J; Buckman BO; Vergona R Thromb Haemost; 2007 Jan; 97(1):54-61. PubMed ID: 17200771 [TBL] [Abstract][Full Text] [Related]
12. Maintaining long-term vessel patency in microvascular surgery using tissue-type plasminogen activator. Romano JE; Biel MA Otolaryngol Head Neck Surg; 1991 Sep; 105(3):391-5. PubMed ID: 1945424 [TBL] [Abstract][Full Text] [Related]
13. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity. Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999 [TBL] [Abstract][Full Text] [Related]
14. [Plasminogen activator of tissue type. Physiology, pathophysiology and clinical value]. Korninger C Wien Klin Wochenschr; 1985 Nov; 97(22):832-40. PubMed ID: 2934899 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological thrombolysis: one more weapon for free-flap salvage. D'Arpa S; Cordova A; Moschella F Microsurgery; 2005; 25(6):477-80. PubMed ID: 16142790 [TBL] [Abstract][Full Text] [Related]
16. Vascular complications and microvascular free flap salvage: the role of thrombolytic agents. Chang EI; Mehrara BJ; Festekjian JH; Da Lio AL; Crisera CA Microsurgery; 2011 Oct; 31(7):505-9. PubMed ID: 21630338 [TBL] [Abstract][Full Text] [Related]
17. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?]. Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413 [TBL] [Abstract][Full Text] [Related]
18. Kinking of pedicle vessels and its effect on blood flow and patency in free flaps: an experimental study in rats. Biglioli F; Rabagliati M; Gatti S; Brusati R J Craniomaxillofac Surg; 2004 Apr; 32(2):94-7. PubMed ID: 14980590 [TBL] [Abstract][Full Text] [Related]
19. [Local thrombolysis in peripheral arterial occlusion]. Hess H Herz; 1989 Feb; 14(1):12-21. PubMed ID: 2522076 [TBL] [Abstract][Full Text] [Related]
20. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Kaiser B; Fareed J Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]